Search results
Results From The WOW.Com Content Network
Janus particles are special types of nanoparticles or microparticles whose surfaces have two or more distinct physical properties. [1] [2] This unique surface of Janus particles allows two different types of chemistry to occur on the same particle. The simplest case of a Janus particle is achieved by dividing the particle into two distinct ...
In ancient Roman religion and myth, Janus ( / ˈdʒeɪnəs / JAY-nəs; Latin: Ianvs [ˈi̯aːnʊs]) is the god of beginnings, gates, transitions, time, duality, doorways, [2] passages, frames, and endings. He is usually depicted as having two faces. The month of January is named for Janus ( Ianuarius ). [3] According to ancient Roman farmers ...
Baricitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits Janus kinase 1 with a half maximal inhibitory concentration (IC 50) of 5.9 nM and Janus kinase 2 with an IC 50 of 5.7 nM. Tyrosine kinase 2, which belongs to the same enzyme family, is affected less (IC 50 = 53 nM), and Janus kinase 3 far less (IC 50 > 400 nM).
Ubiquitin specific peptidase 18 ( USP18 ), also known as UBP43, is a type I interferon receptor repressor and an isopeptidase. In humans, it is encoded by the USP18 gene. [5] USP18 is induced by the immune response to type I and III interferons, and serves as a negative regulator of type I interferon, but not type III interferon.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
A Janus molecule (or Janus-faced molecule) is a molecule which can represent both beneficial and toxic effects. The term Janus-faced molecule is derived from the ancient Roman god, Janus. Janus is depicted as having two faces; one facing the past and one facing the future. [1] This is synonymous to a Janus molecule having two distinct purposes ...
Ruxolitinib is a Janus kinase inhibitor. [6] It was developed and marketed by Incyte Corp in the US under the brand name Jakafi, [6] and by Novartis elsewhere in the world, under the brand name Jakavi. [14] It was approved for medical use in the United States in 2011, [15] and in the European Union in 2012. [8]
The Janus Experiments investigated the effects of exposure to neutron radiation and gamma radiation on mice and dogs. They consisted of ten large scale experiments conducted at Argonne National Laboratory from 1972 to 1989. To explore various relationships, the studies varied radiation type, dose rates, total dose and fractionation.